Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 25;46(9):9376-9385.
doi: 10.3390/cimb46090555.

Molecular Analysis of High-Grade Serous Ovarian Carcinoma Exhibiting Low-Grade Serous Carcinoma and Serous Borderline Tumor

Affiliations

Molecular Analysis of High-Grade Serous Ovarian Carcinoma Exhibiting Low-Grade Serous Carcinoma and Serous Borderline Tumor

Kosuke Kanno et al. Curr Issues Mol Biol. .

Abstract

Ovarian cancer is classified as type 1 or 2, representing low- and high-grade serous carcinoma (LGSC and HGSC), respectively. LGSC arises from serous borderline tumor (SBT) in a stepwise manner, while HGSC develops from serous tubal intraepithelial carcinoma (STIC). Rarely, HGSC develops from SBT and LGSC. Herein, we describe the case of a patient with HGSC who presented with SBT and LGSC, and in whom we analyzed the molecular mechanisms of carcinogenesis. We performed primary debulking surgery, resulting in a suboptimal simple total hysterectomy and bilateral salpingo-oophorectomy due to strong adhesions. The diagnosis was stage IIIC HGSC, pT3bcN0cM0, but the tumor contained SBT and LGSC lesions. After surgery, TC (Paclitaxel + Carbopratin) + bevacizumab therapy was administered as adjuvant chemotherapy followed by bevacizumab as maintenance therapy. The tumor was chemo-resistant and caused ileus, and bevacizumab therapy was conducted only twice. Next-Generation Sequencing revealed KRAS (p.G12V) and NF2 (p.W184*) mutations in all lesions. Interestingly, the TP53 mutation was not detected in every lesion, and immunohistochemistry showed those lesions with wild-type p53. MDM2 was amplified in the HGSC lesions. DNA methylation analysis did not show differentially methylated regions. This case suggests that SBT and LGSC may transform into HGSC via p53 dysfunction due to MDM2 amplification.

Keywords: MDM2; high-grade serous carcinoma; low-grade serous carcinoma; ovarian cancer; serous borderline tumor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 2
Figure 2
Copy number alterations. (a) SBT; (b) LGSC; (c) HGSC. The difference between MDM2 is greater in HGSC compared to SBT and LGSC.
Figure 3
Figure 3
Epigenetic analysis of cancer-related genes. Green-colored cells indicate hypermethylated genes. Red-colored cells indicate hypomethylated genes. Blue-colored cells indicate equally methylated genes. No oncogenes are hypomethylated and no tumor suppressor genes are hypermethylated specifically in HGSC.
Figure 1
Figure 1
Hematoxylin and eosin (HE) staining of each lesion. (a) The SBT lesion at 200× g magnification. (b) The LGSC lesion at 200× g magnification. (c) HGSC lesion at 200× g magnification. (d) The arrow indicates junction of SBT and LGSC. SBT is contiguous with LGSC at 400× g magnification. (e) The arrow head indicates junction of LGSC and HGSC. LGSC is contiguous with HGSC at 100× g magnification.

Similar articles

Cited by

References

    1. Cancer Statistics Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare) [(accessed on 6 October 2022)]. Available online: https://ganjoho.jp/reg_stat/statistics/data/dl/en.html.
    1. Nagase S. Patient Annual Report for 2022. Acta Obstet. Gynaecol. Jpn. 2022;74:2345–2402.
    1. Kurman R.J., Carcangiu M.L., Young R.H., Herrington C.S., editors. World Health Organization Classification of Tumours. 4th ed. International Agency for Research on Cancer; Lyon, France: 2014. WHO Classification of Tumours of Female Reproductive Organs.
    1. Shih I.-M., Kurman R.J. Ovarian Tumorigenesis. Am. J. Pathol. 2004;164:1511–1518. doi: 10.1016/S0002-9440(10)63708-X. - DOI - PMC - PubMed
    1. Shih I.-M., Kurman R.J. Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges. Clin. Cancer Res. 2005;11:7273–7279. doi: 10.1158/1078-0432.CCR-05-0755. - DOI - PubMed

LinkOut - more resources